Background and aim <p>Monoclonal immunoassays offer greater specificity than polyclonal assays for cortisol measurement, necessitating assay-specific cut-off limits, which have not yet been defined for the insulin tolerance test (ITT). The study aim was to define the normative cortisol response to the ITT with the first- and second-generation Roche Elecsys<sup>®</sup>Cortisol immunoassays (Elecsys<sup>®</sup>Cort I and II).</p> Methods <p>Ninety participants underwent an ITT after an overnight fast. Blood samples were analysed by both Elecsys<sup>®</sup>Cort I and II. The normative cortisol cut-off limit to the ITT was defined as the 2.5th percentile of the peak cortisol level for each assay. The percentage of healthy participants with peak cortisol below the cut-off limits defined for the ACTH test, 500 nmol/L for Elecsys<sup>®</sup>Cort I and 420 nmol/L for Elecsys<sup>®</sup>Cort II, respectively, was calculated as the false-positive rate.</p> Results <p>The mean peak cortisol was 608 ± 102 nmol/L with Elecsys<sup>®</sup>Cort I and 501 ± 89 nmol/L with Elecsys<sup>®</sup>Cort II. The 2.5th percentile was 404 nmol/L with Elecsys<sup>®</sup>Cort I and 320 nmol/L with Elecsys<sup>®</sup>Cort II; 5th percentiles were 451 nmol/L and 348 nmol/L, respectively. False-positive rates were 15% with Elecsys<sup>®</sup>Cort I and 18% with Elecsys<sup>®</sup>Cort II.</p> Conclusion <p>Elecsys<sup>®</sup>Cort II demonstrated a lower normative cortisol response to the ITT compared with Elecsys<sup>®</sup>Cort I, and the commonly used ACTH test thresholds. These data underline the need for assay- and test-specific cut-off limits to confirm or reject adrenal insufficiency.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Defining normative cortisol responses to the insulin tolerance test: A comparison of Elecsys®Cort I and II assays

  • Sema Okutan,
  • Stina Willemoes Borresen,
  • Linda Hilsted,
  • Ulla Feldt-Rasmussen,
  • Marianne Klose

摘要

Background and aim

Monoclonal immunoassays offer greater specificity than polyclonal assays for cortisol measurement, necessitating assay-specific cut-off limits, which have not yet been defined for the insulin tolerance test (ITT). The study aim was to define the normative cortisol response to the ITT with the first- and second-generation Roche Elecsys®Cortisol immunoassays (Elecsys®Cort I and II).

Methods

Ninety participants underwent an ITT after an overnight fast. Blood samples were analysed by both Elecsys®Cort I and II. The normative cortisol cut-off limit to the ITT was defined as the 2.5th percentile of the peak cortisol level for each assay. The percentage of healthy participants with peak cortisol below the cut-off limits defined for the ACTH test, 500 nmol/L for Elecsys®Cort I and 420 nmol/L for Elecsys®Cort II, respectively, was calculated as the false-positive rate.

Results

The mean peak cortisol was 608 ± 102 nmol/L with Elecsys®Cort I and 501 ± 89 nmol/L with Elecsys®Cort II. The 2.5th percentile was 404 nmol/L with Elecsys®Cort I and 320 nmol/L with Elecsys®Cort II; 5th percentiles were 451 nmol/L and 348 nmol/L, respectively. False-positive rates were 15% with Elecsys®Cort I and 18% with Elecsys®Cort II.

Conclusion

Elecsys®Cort II demonstrated a lower normative cortisol response to the ITT compared with Elecsys®Cort I, and the commonly used ACTH test thresholds. These data underline the need for assay- and test-specific cut-off limits to confirm or reject adrenal insufficiency.